Dr. Rodney JY Ho is an award-winning entrepreneur, scientist and professor of pharmaceutics and bioengineering at the University of Washington and Executive Director of WE-REACH, a NIH-designated innovation hub. An elected fellow of the National Academy of Inventors, AAAS, and AAPS, he is internationally recognized for his work in long-acting, targeted drug combination therapies for HIV and cancer.
He leads the NIH- and WHO-funded TLC-ART program, advancing long-acting injectable nanoparticle (DcNPs) platforms for synchronized delivery of HIV drugs such as tenofovir, lamivudine and dolutegravir (TLD) and cancer drug combination containing gemcitabine and paclitaxel. Dr. Ho currently serves on the NIH National Cancer Institute Council, WHO UNITAID, and the LEAP executive leadership team for long-acting HIV therapeutics.
He holds over 21 patents, has founded multiple biotech startups, and is the author of Biotechnology & Biopharmaceuticals. He has published 200+ works and is editor of the Journal of Pharmaceutical Sciences.
His formal training includes undergraduate training in Biochemistry from University of California, Davis, MS and PhD from University of Tennessee, focusing on Drug-targeting. He completed an Infectious Diseases Fellowship at Stanford University School of Medicine, Stanford, California.
